Free Trial

BioAtla Q1 2023 Earnings Report

BioAtla logo
$0.37 -0.02 (-4.92%)
As of 03/28/2025 04:00 PM Eastern

BioAtla EPS Results

Actual EPS
-$0.58
Consensus EPS
-$0.66
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

BioAtla Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioAtla Announcement Details

Quarter
Q1 2023
Time
N/A

Conference Call Resources

Remove Ads

BioAtla Earnings Headlines

BioAtla price target lowered to $10 from $13 at BTIG
Has Trump finally met his match?
Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance to walk away with gains as high as 235%, 459%, and 700% - all while the stock market got cut in half. Could he be right again?
BioAtla announces restructuring, to cut over 30% of workforce
BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript
BioAtla Cuts 30% of Jobs in Restructuring Effort
See More BioAtla Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioAtla? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioAtla and other key companies, straight to your email.

About BioAtla

BioAtla (NASDAQ:BCAB), a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

View BioAtla Profile

More Earnings Resources from MarketBeat